No Data
No Data
Ruili Medical & Aesthetic (02135) announced annual results, loss attributable to shareholders of 32.457 million yuan, an increase of 103.99% year-on-year
According to the Zhitong Finance App, Ruili Medical & Aesthetic (02135) announced annual results for the year ended December 31, 2023. The group achieved revenue of 189 million yuan (RMB, same below) during the period, an increase of 15.11% over the previous year; losses attributable to shareholders were 32.457 million yuan, an increase of 103.99% over the previous year; and the basic loss per share was 7.77 points. According to the announcement, the main reason for the increase in revenue and continued losses is that in the first month of 2023, the business of medical institutions in Zhejiang and Anhui regions was still affected by the large-scale COVID-19 outbreak, which prevented most customers from visiting the group's institutions, making the company
瑞麗醫美:截至2023年12月31日止年度年度業績公告
Ruili Medical & Aesthetic (02135) cut 1,671 billion shares due to share consolidation on a “5 and 1” basis
Ruili Medical & Aesthetic (02135) issued an announcement to cut 1,671 billion shares due to share consolidation on a “5 and 1” basis...
Raily Aesthetic Medicine International Holdings Limited's (HKG:2135) 39% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Raily Aesthetic Medicine International Holdings Limited (HKG:2135) shares have had a horrible month, losing 39% after a relatively good period beforehand. The recent drop completes a disastrous twe
Ruili Medical & Aesthetic (02135): The share merger will take effect on March 19
Ruili Medical & Aesthetic (02135) issued an announcement. Since all conditions for the share merger have been met, the share merger will be 202...
[Company Profit Alert] Ruili Medical Aesthetic (02135) expects losses to increase to 32 million yuan last year
Jinwu Financial News | Ruili Medical & Aesthetic (02135) issued a profit warning. The Group expects revenue of approximately RMB 189 million for the year ended December 31, 2023 (2022: revenue of approximately RMB 165 million); and for the year ended December 31, 2023, losses attributable to owners of the parent company were approximately RMB 32 million. In the same period last year, parent company owners should account for losses of approximately RMB 16 million. According to the announcement, the continued loss was mainly due to the first month of 2023. The business of medical institutions in Zhejiang and Anhui was still affected by the large-scale COVID-19 outbreak, leading to the majority
No Data